Feasibility of IDEOM's Clinical Framework to Optimize Psoriatic Arthritis Care: A Cross-sectional Quality Improvement Study [0.03%]
IDEOM临床框架优化银屑病关节炎护理的可行性：一项质量改进横断面研究
Gretchen D Ball,Hassan Hamade,Sarah Romanelli et al.
Gretchen D Ball et al.
Jennifer Roux,Luke Horton,Arash Babadjouni et al.
Jennifer Roux et al.
Objective: Ferulic acid (FA) is gaining popularity in skincare products for its antioxidant and anti-inflammatory properties. However, its effectiveness and optimal use in humans require critical evaluation. This study ai...
Safety Evaluation of Topical Products Containing Live Cultures and Ferment of Cutibacterium Acnes Subspecies Defendens Strain XYCM42 in Individuals Predisposed to Acne Vulgaris [0.03%]
含活菌和Defendens亚种XYCM42株发酵产物的外用化妆品在易患痤疮人群中的安全评估
Mona L Alqam,Brian C Jones,Thomas M Hitchcock
Mona L Alqam
Background: For individuals with acne-prone skin, identifying a topical regimen that does not lead to progression of their inflammatory issues often poses a challenge. A topical skin probiotic regimen containing a specifi...
A Review of Neoadjuvant PD-1 Inhibitors in the Setting of Cutaneous Malignancies [0.03%]
用于皮肤恶性肿瘤的新辅助PD-1抑制剂的回顾
Ariel R Darnall,David Baltazar,Dathan Hamann et al.
Ariel R Darnall et al.
Considering the rapid pace of developments in the field of cancer immunotherapy, continuous updates on the topic are critical for the medical community. With incidences of cutaneous malignancies on the rise, it is more imperative than ever ...
The Treatment of Pembrolizumab-Induced Pruritus with Topical Roflumilast Cream 0.3% Once Daily [0.03%]
局部罗氟司特乳膏治疗派姆单抗诱导的瘙痒症
Laura Lomax
Laura Lomax
Pembrolizumab is an immune checkpoint inhibitor that is used in the treatment of various cancers. The reported mode of action of pembrolizumab is via binding to the PD-1 receptor which leads to blocking both immune-suppressing ligands, PD-L...
Sandi Assaf,Peter Lio,James Q Del Rosso
Sandi Assaf
Atopic dermatitis (AD) commonly presents in both children and adults with pruritic, eczematous lesions that can have a substantial impact on quality of life. Current biologics approved for AD include dupilumab, an IL-4 receptor alpha inhibi...
Haowei Han,Faraz Yousefian,Ciaran Smythe et al.
Haowei Han et al.
Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series [0.03%]
特拉鲁莫单抗治疗Dupixent相关性关节痛的疗效观察：多中心病例系列研究
Ana B W Greenberg,Mona Shahriari,Michael C Cameron et al.
Ana B W Greenberg et al.
Atopic dermatitis (AD) is a chronic inflammatory skin condition that often requires systemic treatment to achieve optimal clinical outcomes. The clinical and immunological heterogeneity of AD necessitates the use of various therapies to max...
Red-Light Photodynamic Therapy with 10% Aminolevulinic Acid (ALA) Following Microneedling in the Treatment of Facial Actinic Keratosis: Cosmetic and Clinical Outcomes [0.03%]
光动力治疗面部光线性角化病的美容和临床效果：在微针治疗后使用10％氨基叶酸（ALA）进行红灯光动力疗法
Gary Goldenberg,Ziv Schwartz,Faraz Yousefian
Gary Goldenberg
Objective: We evaluated the cosmetic outcome and clearance of actinic keratoses (AKs) using photodynamic therapy (PDT) with microneedling-assisted delivery of 10% aminolevulinic acid (ALA) gel (Ameluz®, Biofrontera, Wobu...
Impact of the COVID-19 Pandemic on the Diagnosis and Treatment of Cutaneous Melanoma in a Public Health Service in Brazil [0.03%]
巴西公共卫生服务机构的COVID-19大流行对皮肤黑色素瘤诊断和治疗的影响
Ana Carolina da Silva Carvalho,Carolina de Magalhães Ledsham Lopes,Amanda Ribeiro Lobo et al.
Ana Carolina da Silva Carvalho et al.
Objective: The authors sought to evaluate the impact of the COVID-19 pandemic on the incidence, tumor thickness, and time between diagnosis and first treatment of cutaneous melanoma patients. ...